Coming Events
2007 Medical Convention Information
Cardiovascular Research Foundation (CRF)
Annual Interventional Cardiology Fellows Course (Fellows)
April 11 – 14
John B. Hynes Veterans Memorial Convention Center
Sheraton Boston Hotel
Boston, Massachusetts
American Association of Critical-Care Nurses (AACN)
National Teaching Institute & Critical-Care Expo
May 19 – 24
Georgia World Congress Center
Atlanta, Georgia
Transcatheter Cardiovascular Therapeutics (TCT)
TCT 2007
Oct. 20 – 25
Washington Convention Center
Washington, DC
American College of Clinical Pharmacy (ACCP)
Annual Meeting
Oct. 14 – 17
Colorado Convention Center
Denver, Colorado
The Society for Cardiovascular Angiography and Interventions (SCAI) -
Fellows Program (SCAI Fellows-Fall)
Date/Location: TBD
American Heart Association (AHA)
Scientific Sessions
Nov. 4 – 7
Orange County Convention Center
Orlando, Florida
American Society of Health-System Pharmacists (ASHP) 42nd Midyear Clinical Meeting
Dec. 2 – 6
Sands Expo and Venetian Hotel
Las Vegas, Nevada
Safety Considerations
ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (
10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete
prescribing information.